Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 279 across all filing types
Latest filing 2020-09-07 Regulatory Filings
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1884 characters) and contains the header 'RNS Number : 2343Y'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange. The text explicitly mentions RNS as the news service approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. Since this is a specific, non-standard regulatory announcement that doesn't fit into the defined categories like ER, 10-K, or DIV, and it originates from the RNS system, the most appropriate classification is the general regulatory filing fallback category.
2020-09-07 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half Year Report' for Diaceutics PLC for the period ended 30 June 2020. It contains comprehensive financial statements, including revenue, gross profit, EBITDA, and adjusted earnings per share, as well as a detailed business review, operational highlights, and outlook. It is not a mere announcement or certification, but the substantive interim financial report itself. H1 2020
2020-09-07 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3303 characters) released via RNS (RNS Number : 2435X) from Diaceutics PLC. The title is "Notice of results Analyst & investor briefing". The text explicitly states that the company "announces it will release its interim results for the six months ended 30 June 2020 on Monday, 7 September 2020" and provides details for subsequent analyst and investor briefings. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report (in this case, interim results, which would typically be an IR filing) is classified as a Report Publication Announcement (RPA).
2020-08-27 English
New contract win for DXRX platform
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated July 22, 2020. It announces a 'significant new client contract win' and provides details about the contract value and the company's platform (DXRX). The text concludes with standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. This structure is characteristic of a general regulatory news announcement, which is not covered by more specific categories like ER, DIV, or DIRS. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (3448 chars) is short, but it is reporting a specific event (contract win) rather than announcing the publication of a separate, larger report, so RPA is less suitable than RNS for this type of operational news.
2020-07-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document explicitly starts with 'RNS Number : 4650S' and mentions that the information is provided by RNS, the news service of the London Stock Exchange, approved by the Financial Conduct Authority (FCA). The content is a 'TR-1: Standard form for notification of major holdings,' which details changes in voting rights held by an individual (Elizabeth Considine) in Diaceutics PLC, crossing a threshold (from 7.92% to 6.56%). This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2020-07-09 English
Trading update
Earnings Release Classification · 100% confidence The document is identified by the RNS Number header and explicitly states it is a "Trading update for the six months ended 30 June 2020." This content provides key financial highlights (Sales, Net cash) and operational updates for an interim period (H1 2020). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is a trading update, it covers the full six-month period comprehensively enough to be classified as the interim report summary, rather than just an Earnings Release (ER) which is typically just the initial announcement of key figures. The document also mentions that the full 'interim results' are expected later, suggesting this is a pre-release or trading update summary, but given the depth of financial figures provided for the period, IR is the most appropriate classification over ER or RPA. H1 2020
2020-07-08 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.